FDA/The Osteosarcoma Institute (OSI) Workshop: Advancing Osteosarcoma Drug Development – Connecting Research and Regulatory Pathways for Improved Outcomes

The FDA Oncology Center of Excellence (OCE) and The Osteosarcoma Institute (OSI) are hosting a workshop focused on addressing key challenges in osteosarcoma drug development. This event aims to bring together stakeholders from patient advocacy, academic research, regulatory agencies, and the biopharmaceutical industry to identify barriers and collaborate on solutions for advancing clinical therapies.

Topics Will Include:

1. Identifying promising drug candidates
2. Addressing molecular heterogeneity
3. Optimizing clinical trial endpoints
4. Incorporating innovative study designs

Event Goals:

1. To convene key stakeholders to share perspectives on the challenges to, and identify opportunities for, advancing clinical development of therapies for osteosarcoma through collaboration and communication.
2. To identify opportunities to increase efficiency within osteosarcoma drug development.
3. To develop strategies to address the most significant challenges in clinical trials design and implementation in osteosarcoma.

Visit the event page for more information.